Immunocore Holdings plc

IMCR72

$32.62arrow_drop_down4.50%-$1.53

IMCR72

$32.62

arrow_drop_down4.50%-$1.53

Performance History

Key Stats
Open	$34.04
Prev. Close	$34.17
EPS	-0.95
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	32.60	34.30
52 Week Range	29.72	76.98

Ratios







EPS	-0.95

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Immunocore Holdings plc (IMCR)

Immunocore Holdings plc (IMCR) is a biotechnology company that focuses on the discovery and development of T cell receptor-based drugs for the treatment of cancer and other diseases. The company's proprietary platform, called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer), harnesses the power of the immune system to target and destroy cancer cells. This innovative approach has the potential to revolutionize cancer treatment and improve patient outcomes.

IMCR stock has a rich price history, with fluctuations that reflect the progress and prospects of the company. Investors closely follow the stock's performance, analyzing trends and making informed decisions. The stock price can be influenced by various factors, such as clinical trial results, regulatory approvals, collaborations, and market dynamics. As the company advances its pipeline and reaches key milestones, the stock price may experience significant movements.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Bahija Jallal Ph.D.
Headquarters: Abingdon
Employees: 408
Exchange: NASDAQ

add Immunocore Holdings plc to watchlist

Keep an eye on Immunocore Holdings plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the 52-week high and low for Immunocore Holdings plc (IMCR)?

For Immunocore Holdings plc (IMCR), the 52-week high is $76.98, which is 135.99% from the current price. The 52-week low is $29.72, the current price is 9.76% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is Immunocore Holdings plc's (IMCR) price per share?

The current price per share for Immunocore Holdings plc (IMCR) is $32.62. The stock has seen a price change of -$1.54 recently, indicating a -4.51% change. This reflects the stock's recent market performance and investor sentiment.

help

Is Immunocore Holdings plc (IMCR) a growth stock?

Immunocore Holdings plc (IMCR) has shown an average price growth of -3.55% over the past three years. It has received a score of 53 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Immunocore Holdings plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Immunocore Holdings plc (IMCR) stock price performance year to date (YTD)?

As of the latest data, Immunocore Holdings plc (IMCR) has a year-to-date price change of -54.47%. Over the past month, the stock has experienced a price change of 1.34%. Over the last three months, the change has been -11.77%. Over the past six months, the figure is -41.59%.

help

Is Immunocore Holdings plc (IMCR) a profitable company?

Immunocore Holdings plc (IMCR) has a net income of -$55.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.6% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $249.43M, with a revenue growth rate of 73.53%, providing insight into the company's sales performance and growth. The gross profit is $248.39M. Operating income is noted at -$59.65M. Furthermore, the EBITDA is -$64.89M.

help

What is the market capitalization of Immunocore Holdings plc (IMCR)?

Immunocore Holdings plc (IMCR) has a market capitalization of $1.63B. The average daily trading volume is 33.38, indicating the stock's liquidity and investor engagement.

News

Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights

Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire

PRESS RELEASES

Jun 1, 2024

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

PRESS RELEASES

May 31, 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

PRESS RELEASES

May 29, 2024

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

ANALYST RATINGS

May 24, 2024

Analyst Expectations For Immunocore Hldgs's Future

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Immunocore Holdings plc (IMCR)

Keep an eye on Immunocore Holdings plc

Frequently Asked Questions

What is the 52-week high and low for Immunocore Holdings plc (IMCR)?

What is Immunocore Holdings plc's (IMCR) price per share?

Is Immunocore Holdings plc (IMCR) a growth stock?

What is Immunocore Holdings plc (IMCR) stock price performance year to date (YTD)?

Is Immunocore Holdings plc (IMCR) a profitable company?

What is the market capitalization of Immunocore Holdings plc (IMCR)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level